|
**Overview**: Insulin-Like Growth Factor I Growth Hormone Panel**Introduction**: The Insulin-Like Growth Factor I Growth Hormone Panel is a diagnostic tool designed to assess growth hormone deficiency using serum samples. In India, GHD in children causes short stature (~3-5 percent affected), while adult GHD leads to reduced muscle mass, fatigue, and CVD risk. IGF-1 serves as a surrogate marker for GH secretion. High morbidity from under-testing in rural/low-SES children with growth failure or adults with pituitary disease, limited endocrine labs, delayed GH therapy leading to permanent short stature or metabolic issues. Per endocrinology practices aligned with ICMR and Indian Society for Pediatric and Adolescent Endocrinology guidelines, the test employs immunoassay for IGF-I and growth hormone over 1-2 days with high accuracy, valuable for screening GHD before stimulation testing. This diagnostic falls under hormonal screening and targets children with short stature or adults with pituitary dysfunction, addressing accurate detection to guide further evaluation or GH replacement. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise GH axis assessment and improving outcomes. Its serum-based approach ensures reliable measurement.**Other Names**: IGF-I GH Pnl.**FDA Status**: FDA approved, CLIA certified for endocrinology/immunology, compliant with 2025 standards.**Historical Milestone**: IGF-1/GH panel standard; in India, used in growth clinics.**Purpose**: The test assesses 2 parameters including IGF-I to guide growth hormone deficiency screening, assess GH axis, inform therapy.**Test Parameters**: 1. IGF-I, 2. Growth Hormone.**Pretest Condition**: Fasting 10-12 hours recommended; patients should report growth issues.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on height velocity, puberty, pituitary history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated GHD including short stature, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or malnutrition can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Low IGF-1 indicates possible GHD, necessitating specialist input.**Specialist Consultation**: Endocrinologists should be consulted for management.**Additional Supporting Tests**: GH stimulation test, MRI pituitary for confirmation.**Test Limitations**: IGF-1 age-dependent; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Growth Studies India 2023. |
